Regorafenib Plus Chemo and Nivolumab Shows Activity in Esophagogastric Cancer
First-line regorafenib plus nivolumab and chemotherapy has shown activity in patients with HER2-negative metastatic esophagogastric cancer in a phase 2 trial.
First-line regorafenib plus nivolumab and chemotherapy has shown activity in patients with HER2-negative metastatic esophagogastric cancer in a phase 2 trial.
Vitamin D3 supplementation may improve relapse-free survival in certain patients with gastrointestinal tract cancers, data suggest.
A meta-analysis suggests that delaying chemotherapy in patients with asymptomatic, advanced cancer does not worsen overall survival.
A blood-based test called SPOT-MAS can determine the presence and location of multiple cancers, a new study suggests.
Zolbetuximab plus mFOLFOX6 has demonstrated efficacy in a phase 2 trial of patients with CLDN18.2+ advanced gastric/GEJ cancer.
Neoadjuvant chemotherapy or chemoradiotherapy improves outcomes in patients with esophageal or gastroesophageal junction cancer, a meta-analysis suggests.
If approved, zolbetuximab would be the first CLDN18.2-targeted therapy for advanced gastric and gastroesophageal cancers in the US.
ASCO has released recommendations outlining how to treat patients with gastrointestinal cancer while chemotherapy drugs are in short supply.
Adding nivolumab to adjuvant chemotherapy did not improve relapse-free survival in a phase 3 trial of patients with gastric/GEJ cancer.
Higher levels of certain sex hormones are associated with an increased risk of some gastrointestinal cancers, a meta-analysis suggests.